Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multi-Institutional Pilot Study of Nivolumab and Radiation Therapy Versus Nivolumab and Ipilimumab as Adjuvant Therapy for Merkel Cell Carcinoma

NCT03798639 is registered in ClinicalTrials.gov with Claire Verschraegen as lead sponsor.

NCT NCT03798639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03798639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multi-Institutional Pilot Study of Nivolumab and Radiation Therapy Versus Nivolumab and Ipilimumab as Adjuvant Therapy for Merkel Cell Carcinoma
Lead sponsor
Claire Verschraegen
Phase
Phase 1
Overall status
Completed
Start date
January 7, 2019
Completion date
December 2, 2022
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

merkel cell carcinoma, pathologic stage iiia merkel cell carcinoma ajcc v8, pathologic stage iiib merkel cell carcinoma ajcc v8